SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets
CTG 8.360+0.4%2:23 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: richardred11/21/2016 11:36:13 AM
  Read Replies (2) of 6084
 
Added to DSCI today. IMO the company kinda mortgaged itself with the BioD acquisition terms. However IMO compelling High risk / High reward. IMO the latest acquisition along with the latest divestiture, gives scale & compelling margins. This on a on a small cap, formally unprofitable company. I see their burn products being medical necessities . I could get burned, but the healing process has started.

P.S. The scale of wound care market by way of the BioD acquisition, although still small. IMO make it a compelling niche for a bigger player's medical portfolio. 3M - Allergen - J&J come to mind.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext